Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03807544 · ClinicalTrials.gov registry record · NA

Treatment Parameters for the Empower Neuromodulation System (ENS)

A NA study of Alcohol Use Disorder, sponsored by Theranova, L.L.C..

Completed
Registry status
NA
Development phase
17
Enrollment target
1
Study location

NCT03807544 is a NA study of Alcohol Use Disorder that has completed, run by Theranova, L.L.C.. The registered enrollment target is 17 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03807544, a NA study of Alcohol Use Disorder, has completed, sponsored by Theranova, L.L.C..

COMPLETED
Registry status
NA
Development phase
17 participants
Enrollment target
1
Study location

Study Summary

The subject will be administered a treatment at a treatment location and then be asked if he/she believes it is the active treatment, sham treatment, or does not know. A clinical-grade nerve conduction assessment system will be used both to provide electrical stimulation at four locations to record peripheral responses. The subject will self-administer two treatment sessions at two active treatment sites.

Conditions Studied

Interventions

  • DEVICE TENS

Study Locations (1)

California

  • TheraNova - San Francisco

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2019-01-15
Est. Completion 2019-03-13
Phase NA

Sponsor

Theranova, L.L.C.

11 total trials

What the Registry Record Tells You About NCT03807544

The ClinicalTrials.gov registry entry for NCT03807544 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (95% lower). The listed sponsor is Theranova, L.L.C., which has 11 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which TENS is the first listed.

NCT03807544 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03807544 about?

NCT03807544 is a clinical study titled "Treatment Parameters for the Empower Neuromodulation System (ENS)". The subject will be administered a treatment at a treatment location and then be asked if he/she believes it is the active treatment, sham treatment, or does not know. A clinical-grade nerve conduction assessment system will be used both to provide electrical stimulation at four locations to record ...

What is the current status of trial NCT03807544?

This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2019-01-15. Estimated completion is 2019-03-13.

What conditions does trial NCT03807544 study?

This clinical trial studies the following conditions: Alcohol Use Disorder.

What interventions are being tested in trial NCT03807544?

The interventions under investigation include: TENS (DEVICE).

Who is sponsoring clinical trial NCT03807544?

This trial is sponsored by Theranova, L.L.C., which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03807544 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.